医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pacific Life Re Opens New Branch and Ready to Write Onshore Reinsurance Business in Korea

2016年03月31日 AM11:05
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

Pacific Life Re Limited, Korea Branch (“Pacific Life Re Korea”) has received regulatory approval from the Financial Services Commission (FSC) to commence writing onshore reinsurance business in Korea.

Pacific Life Re Korea is part of Pacific Life Re, the reinsurance division of the Pacific Life group. Pacific Life Re has existing offices in Asia, Europe, Australia, and North America. The ultimate parent is Pacific Mutual Holding Company, a US-based mutual life insurance company founded in 1868 with over US$137bn in Company Assets, as of December 31, 2015.

“This move demonstrates our on-going commitment to further deepen our footprint in Asia,” says Alex King, Managing Director of Pacific Life Re Asia. “We have been working with our clients in Korea since 2009, operating out of our regional hub in Singapore. The recent market reforms present us with a unique opportunity to providing a fresh and innovative approach to life reinsurance in the Korean market.”

Pacific Life Re Division CEO Dave Howell also commented, “This licence represents a further expansion of the Pacific Life Re global brand and its proposition in Asia. With a local team in place, we are enhancing our service proposition to meet the needs of the Korean insurers in the coming years.”

Pacific Life Re has a financial strength credit rating from S&P and Fitch of A+ (stable outlook).

About Pacific Life Re

Pacific Life Re works with clients in the UK, Ireland, Asia, Australia, and North America to manage their mortality, longevity, and morbidity risk. Pacific Life Re Limited is a wholly-owned subsidiary of Pacific LifeCorp, and is regulated by the Prudential Regulation Authority and the Financial Conduct Authority.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160330005480/en/

CONTACT

Pacific Life Re Limited
Simon Jun Chong, +82-2-6226-7510
Head
of Korea
simon.chong@pacificlifere.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続